Israel-based Silexion Therapeutics has released new preclinical findings suggesting that its experimental therapy may hold promise against some of the most challenging-to-treat cancers.

The company announced Thursday that its RNA interference drug, SIL204, showed powerful activity in laboratory tests.

The therapy inhibited up to 97% of pancreatic cancer cells and nearly 90% of colorectal cancer cells.